©2022 Stanford Medicine
A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Not Recruiting
Trial ID: NCT03809078
Purpose
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for
biopsy guidance in patients with suspected prostate cancer.
Official Title
A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Stanford Investigator(s)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Farshad Moradi
Clinical Associate Professor, Radiology - Rad/Nuclear Medicine
Guido A. Davidzon
Clinical Associate Professor, Radiology - Rad/Nuclear Medicine
Geoffrey Sonn
Associate Professor of Urology and, by courtesy, of Radiology (Body MRI)
Pejman Ghanouni, MD, PhD
Associate Professor of Radiology (General Radiology) and, by courtesy, of Neurosurgery, of Obstetrics and Gynecology and of Urology
Eligibility
Inclusion Criteria:
- Suspected prostate cancer
- Planned prostate biopsy
- Able to provide written consent
- Karnofsky performance status of 50 (or ECOG/WHO equivalent)
Exclusion Criteria:
- Patients not capable of getting PET study due to weight, claustrophobia, or inability
to lay still for the duration of the exam
- Metallic implants (contraindicated for MRI)
Intervention(s):
drug: 68Ga RM2
drug: 68Ga-PSMA-11
device: Investigational PET scanner coils and software
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Brittney Williams
650-736-3688